| Landscape of somatic mutations in 560 breast cancer whole-genome sequences S Nik-Zainal, H Davies, J Staaf, M Ramakrishna, D Glodzik, X Zou, ... Nature 534 (7605), 47-54, 2016 | 2160 | 2016 |
| Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for … IF Khouri, M Keating, M Körbling, D Przepiorka, P Anderlini, S O'Brien, ... Journal of Clinical Oncology 16 (8), 2817-2824, 1998 | 1157 | 1998 |
| Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... New England Journal of Medicine 387 (1), 9-20, 2022 | 1113 | 2022 |
| Genome evolution in the allotetraploid frog Xenopus laevis AM Session, Y Uno, T Kwon, JA Chapman, A Toyoda, S Takahashi, ... Nature 538 (7625), 336-343, 2016 | 926 | 2016 |
| Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes H Masuda, KA Baggerly, Y Wang, Y Zhang, AM Gonzalez-Angulo, ... Clinical cancer research 19 (19), 5533-5540, 2013 | 838 | 2013 |
| Bone imaging in metastatic breast cancer T Hamaoka, JE Madewell, DA Podoloff, GN Hortobagyi, NT Ueno Journal of Clinical Oncology 22 (14), 2942-2953, 2004 | 770 | 2004 |
| Role of epidermal growth factor receptor in breast cancer H Masuda, D Zhang, C Bartholomeusz, H Doihara, GN Hortobagyi, ... Breast cancer research and treatment 136, 331-345, 2012 | 756 | 2012 |
| Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell … S Giralt, PF Thall, I Khouri, X Wang, I Braunschweig, C Ippolitti, D Claxton, ... Blood, The Journal of the American Society of Hematology 97 (3), 631-637, 2001 | 704 | 2001 |
| High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 32 (5), 661-672, 2021 | 662 | 2021 |
| A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ... Jama 305 (18), 1873-1881, 2011 | 646 | 2011 |
| Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo S Iemura, TS Yamamoto, C Takagi, H Uchiyama, T Natsume, S Shimasaki, ... Proceedings of the National Academy of Sciences 95 (16), 9337-9342, 1998 | 566 | 1998 |
| International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment S Dawood, SD Merajver, P Viens, PB Vermeulen, SM Swain, TA Buchholz, ... Annals of oncology 22 (3), 515-523, 2011 | 545 | 2011 |
| Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors N Niikura, J Liu, N Hayashi, EA Mittendorf, Y Gong, SL Palla, Y Tokuda, ... Journal of Clinical Oncology 30 (6), 593, 2012 | 464 | 2012 |
| Inflammatory breast cancer: the disease, the biology, the treatment FM Robertson, M Bondy, W Yang, H Yamauchi, S Wiggins, S Kamrudin, ... CA: a cancer journal for clinicians 60 (6), 351-375, 2010 | 449 | 2010 |
| Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term … M De Lima, A Anagnostopoulos, M Munsell, M Shahjahan, N Ueno, ... Blood 104 (3), 865-872, 2004 | 441 | 2004 |
| Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials F Meric-Bernstam, L Brusco, K Shaw, C Horombe, S Kopetz, MA Davies, ... Journal of clinical oncology 33 (25), 2753, 2015 | 418 | 2015 |
| P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells R Nahta, T Takahashi, NT Ueno, MC Hung, FJ Esteva Cancer research 64 (11), 3981-3986, 2004 | 381 | 2004 |
| Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and … IF Khouri, P McLaughlin, RM Saliba, C Hosing, M Korbling, MS Lee, ... Blood, The Journal of the American Society of Hematology 111 (12), 5530-5536, 2008 | 376 | 2008 |
| Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. NT Ueno, G Rondón, NQ Mirza, DK Geisler, P Anderlini, SA Giralt, ... Journal of clinical oncology 16 (3), 986-993, 1998 | 335 | 1998 |
| Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at MD Anderson Cancer Center NT Ueno, AU Buzdar, SE Singletary, FC Ames, MD McNeese, FA Holmes, ... Cancer chemotherapy and pharmacology 40, 321-329, 1997 | 319 | 1997 |
Wendy WoodwardProfessor, MD Anderson Cancer CenterVerified email at mdanderson.org
